Laboratorios Rovi : Risvan approved by the FDA. Rating cut to neutral on valuation grounds
>Risvan obtains FDA approval - Rovi announced that the FDA has authorised the marketing of Risvan (Risperidone ISM) for the treatment of schizophrenia in adults. Risvan is a prolonged-release injectable antipsychotic developed by Rovi for the treatment of schizophrenia in adults, which, as of the first injection, provides immediate and sustained plasmatic drug levels and does not require loading doses or supplementation with oral risperidone. Its European equivalent, ...Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.